Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
IO

NASDAQ · IONS

Ionis Pharmaceuticals, Inc.

Healthcare · Biotechnology

$47.25

Down-$4.19 (-8.15%)

Updated Sep 16, 2026, 7:04 AM

SID Score

4.3/10

Composite research score

Smart Money

59/100

Neutral

Market cap
12.57B
P/E ratio
-49.61
Dividend yield
0.00%
52-week range
$50.01 – $86.74
Volume
6.81M
Avg. volume
2.43M

Price performance

IONS price history

1M range · 20 trading sessions · Daily adjusted prices

IONS closed at $47.25 after 20 trading sessions, down 20.75% for the selected period.

Last close
$47.25
Period change
-20.75%
Period low
$47.25
Period high
$63.57
Daily close
View OHLC price history
IONS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$51.37$51.37$46.715$47.256.81M
Sep 14, 2026$54.88$55.50$51.31$51.445.97M
Sep 11, 2026$55.94$56.16$54.16$54.212.18M
Sep 10, 2026$55.75$55.77$54.91$55.653.06M
Sep 9, 2026$56.38$56.9569$55.695$56.023.04M
Sep 8, 2026$52.15$57.4292$52.15$56.719.18M
Sep 4, 2026$58.36$58.96$57.78$58.092.67M
Sep 3, 2026$60.42$60.42$57.47$58.134.35M
Sep 2, 2026$60.25$61.77$59.775$61.331.85M
Sep 1, 2026$60.37$60.99$59.78$59.881.87M
Aug 31, 2026$61.065$61.065$59.70$60.362.02M
Aug 28, 2026$60.62$61.69$60.35$61.051.85M
Aug 27, 2026$63.48$63.48$62.34$62.431.63M
Aug 26, 2026$63.50$63.55$62.44$63.362.15M
Aug 25, 2026$62.53$64.19$62.19$63.572.44M
Aug 24, 2026$60.535$62.07$59.70$62.042.21M
Aug 21, 2026$59.64$60.915$59.0601$59.742.72M
Aug 20, 2026$60.025$60.41$58.60$58.762.12M
Aug 19, 2026$60.11$61.355$59.61$60.803.14M
Aug 18, 2026$58.405$60.19$58.0237$59.623.19M

Latest IONS news

The latest Smart Investors Daily articles mentioning IONS.

Stock researchCompany · Overview

IONS research

Overview

Company profile and research snapshot.

Company profile

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$83.85
Implied upside
—
Analysts
—
IONS recent ratings
DateFirmRatingTarget
Sep 15, 2026GuggenheimBuy—
Sep 9, 2026BarclaysOverweight—
Sep 8, 2026Morgan StanleyOverweight—
Sep 8, 2026Goldman SachsNeutral—
Sep 8, 2026BMO CapitalMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine. The FDA-approved Zanvastro, chemically known as zilganersen, for adults and children with Alexander disease, has taken the lead as the first approved disease-modifying treatment for the rare neurological disorder. Ionis has set a price of $285,000 per dose […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By